Latest RAC-US Exam Dumps RAPS Exam from Training Expert DumpsQuestion
Pass RAPS Regulatory Affairs Certification (RAC) US PDF Dumps | Recently Updated 100 Questions
The Regulatory Affairs Certification (RAC) is a globally recognized credential for regulatory professionals, and the RAPS RAC-US exam is a key step in achieving this certification. The RAC-US exam is designed to assess the knowledge and skills of regulatory professionals in the United States, covering a range of important regulatory topics. RAC-US exam is a rigorous test of regulatory knowledge and is widely respected as a benchmark for excellence in regulatory affairs.
NEW QUESTION # 29
An inspection of a manufacturing site determines that a number of manufacturing changes have been implemented without obtaining the necessary regulatory clearance. Which of the following actions should the regulatory affairs professional complete FIRST?
- A. Assess the impact of the changes.
- B. Stop product manufacturing.
- C. Review the stability data for the changes.
- D. Establish validation procedures.
Answer: B
NEW QUESTION # 30
In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?
- A. Previous actions taken by regulatory authorities on similar products
- B. Capacity of the manufacturing facilities to fully produce the new product
- C. Regulatory requirements for labeling and packaging
- D. Potential clinical sites for the Phase III clinical trial
Answer: A
NEW QUESTION # 31
During a routine review of promotional materials for a product, a regulatory affairs professional discovers an off-label indication. Which of the following would be the FIRST follow-up action for the regulatory affairs professional to take?
- A. Request that doctors stop using the product for the off-label indication.
- B. Communicate with the sales department to stop using the promotional materials.
- C. Contact the marketing department to recall the product.
- D. Allow doctors to use the product for the off-label indication.
Answer: B
NEW QUESTION # 32
A company is developing a line of products for which no ISO standard of performance is available. As a result, the company wishes to propose developing such a standard. Whom should the company contact in order to start the development of the new standard?
- A. The ISO national member body
- B. The ISO Secretariat
- C. The ISO technical committee in charge of the area
- D. The country's regulatory authority
Answer: A
NEW QUESTION # 33
A company is considering the development of a medical device similar to those already available. Which of the following should be evaluated FIRST when developing a clinical evaluation document?
- A. Adverse event reports
- B. Clinical experience
- C. Literature search
- D. Clinical investigations
Answer: D
NEW QUESTION # 34
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 3
- B. Module 2
- C. Module 1
- D. Module 4
Answer: B
NEW QUESTION # 35
The regulatory authority contacts the regulatory affairs professional regarding a complaint about a drug produced by the company. A consumer reported to the regulatory authority that the tablets have a slightly different color and break easily.
Which of the following actions should the regulatory affairs professional take?
- A. Ask that the regulatory authority provide the batch number printed on the packaging of the affected product.
- B. Ask that the regulatory authority provide the actual product subject to the complaint.
- C. Respond to the regulatory authority that the company will provide copies of the relevant
QC records for batch release. - D. Respond to the regulatory authority that the product subject to the complaint is most likely a counterfeit product.
Answer: A
NEW QUESTION # 36
During face-to-face meetings with the regulatory authority to address submission issues, what is the BEST choice for the number of company representatives who should attend?
- A. As many as required by international standards
- B. The minimum number of attendees necessary to address the issues
- C. As many as government attendees
- D. All senior management from the main office
Answer: B
NEW QUESTION # 37
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?
- A. Documented agreement
- B. Early collaboration
- C. Frequent communication
- D. Follow-up meeting after submission
Answer: C
NEW QUESTION # 38
According to WHO, what are the temperature and humidity conditions for a Zone IVb long- term stability study?
- A. 30c C and 65% RH
- B. 30 C and 35% RH
- C. 30: C and 75% RH
- D. 25: C and 60% RH
Answer: C
NEW QUESTION # 39
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
- A. Class A
- B. Class C
- C. Class B
- D. Class D
Answer: B
NEW QUESTION # 40
A materials supplier informs a company that it intends to stop supplying a material critical to the manufacture of the company's products. What action should the company take FIRST?
- A. Reformulate the products with a replacement material.
- B. Qualify another supplier and execute a supplier agreement.
- C. Complete a gap analysis to identify options.
- D. Review the company's existing Quality Management System
Answer: B
NEW QUESTION # 41
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the vendors comply with GMP requirements?
- A. Request documentation from the sub-contractor.
- B. Request an inspection from a regulatory authority.
- C. Document and perform audits.
- D. Ask the vendor to take responsibility.
Answer: C
NEW QUESTION # 42
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. Randomization scheme and codes
- B. List of lECs or lRBs
- C. Protocol and protocol amendments
- D. Detailed CV of all investigators
Answer: D
NEW QUESTION # 43
A global company has obtained a patent in a specific country for a newly marketed product.
What would be the BEST advice In order to protect the patent in other countries?
- A. Use the Madrid system.
- B. Use the community patent system.
- C. File design patents in target countries.
- D. File patents of interest in target countries.
Answer: D
NEW QUESTION # 44
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
- A. Strengthening a precaution to the product labeling
- B. Deleting an ingredient of the drug product
- C. Deleting a drug substance
- D. Introducing a new analytical method
Answer: A
NEW QUESTION # 45
Which of the following double-blind clinical trial designs would be MOST appropriate for a
Phase III study with a new product intended to treat an acute life-threatening disease with less than optimal available therapy?
- A. Active-controlled
- B. Dose-ranging
- C. Placebo-controlled
- D. Cross-over
Answer: D
NEW QUESTION # 46
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the following?
- A. Adverse environmental impacts
- B. Causes of non-conformities
- C. Late and/or incorrect deliverables
- D. Inadequate training
Answer: B
NEW QUESTION # 47
Company X is planning to acquire the rights for a product marketed by Company Y.
As part of due diligence, what is the MOST important information the Company X regulatory affairs professional should ask senior management to request from Company Y?
- A. Safety issues
- B. Marketing materials
- C. Clinical trial data
- D. Intellectual properly
Answer: A
NEW QUESTION # 48
Which of the following is NOT required to be included in a marketing application?
- A. Final printed label
- B. Administrative forms
- C. Evidence of fee payment
- D. Quality, safety, and efficacy Information
Answer: C
NEW QUESTION # 49
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- B. Examine decisions made about similar products in Country Y to propose the classification of the product.
- C. Apply for review of the additional part of the product as a pharmaceutical product in Country
- D. Submit the product for review as a pharmaceutical product in Country Y.
Answer: C
NEW QUESTION # 50
......
Updated Test Engine to Practice RAC-US Dumps & Practice Exam: https://examsdocs.dumpsquestion.com/RAC-US-exam-dumps-collection.html